The in-situ hybridization market size is expected to advance at a CAGR of 12.8% during 2024–2030, to reach USD 4,017.3 million by 2030. This is ascribed to the rise in the adoption of the ISH technology in diagnostics, for quantifying viral load; increase in the prevalence of chronic as well as genetic diseases, and growth in healthcare expenditure. Additionally, the growing consumer awareness regarding the benefits of the early diagnosis of certain genetic abnormalities and malignancies and of the advantages of in-situ hybridization on the outlook of enhanced visualization, with highly accurate results and fast analysis, could result in a broad range of applications.
Essentially, the increasing use of this technique in the R&D domain and laboratories to diagnose cancer, infectious disorders, and chromosomal abnormalities is the prime factor contributing to the growth in the global market for in-situ hybridization solutions.
Technological advancements are supporting the market expansion with improvements in fluorescent in-situ hybridization and chromogenic in-situ hybridization, which are utilized to differentiate the functions of genes, thus providing useful information about the malignancy. Additionally, many research studies across the world aim to discover, develop, and implement next-generation diagnostic procedures for extracting information on disease pathogenesis and physiological processes.
Furthermore, in-situ hybridization is a promising technology for differentiating dissimilar mRNA species within individual cells in tissue parts. As cancer advances, direct imaging of gene expression at the cellular level offers a unique perspective on the interaction between cancer cells and their microenvironment. In addition, patients and healthcare professionals have recently shown a greater interest in learning about the value of supplementary diagnostics and personalized medications.
Product launches by the key players will further drive the growth in the market for in-situ hybridization solutions over the coming years. For instance, in September 2022, Vizgen launched the MERSCOPE Protein co-detection kit, which enables subcellular spatial multi-omics measurements, along with allowing for the detection of RNA and proteins simultaneously in a standard multiplexed error-robust fluorescence in-situ hybridization (MERFISH) study.
Likewise, developing countries provide lucrative opportunities to the significant market players to strengthen their presence by making high-quality molecular diagnostic tests easily available.
The chromogenic in-situ hybridization (CISH) category is expected to witness a steady CAGR during the forecast period. The key factor driving the growth of this category is the extensive usage of the technology in diagnostic laboratories, as it is a practical, cost-effective, and valid substitute for FISH. CISH, which combines ISH and immunohistochemistry (IHC), is utilized in many pathological and clinical labs for the quantitative evaluation of chromosome translocation, chromosome number, gene amplification, and deletion. Moreover, CISH is cheaper than the FISH technology because the former uses a bright-field microscope, instead of fluorescence microscopes, which is another factor expected to fuel the revenue growth of this category.
Geographically, Asia-Pacific is expected to witness the highest CAGR, of about 13.2%, during the forecast period, on account of the rising need for cytogenetic diagnoses, increasing clinical research on cancer and genetic disorders by biotechnology and pharmaceutical companies, government initiatives, and rising usage of companion diagnostics.
Moreover, the emerging economies of India, China, and Brazil provide considerable growth opportunities to the providers of high-quality molecular diagnostic tests, owing to the rising geriatric population and the growing prevalence of chronic disorders, including various types of cancers. In addition, the favorable healthcare regulations of governments and the development of advanced techniques for proteomic and genomic research are fueling the market advance.
The most-significant in-situ hybridization market players are Abbott Laboratories, F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., Biocare Medical LLC, Bio SB Inc., Thermo Fisher Scientific, DH Life Sciences LLC, NeoGenomics Laboratories Inc., and BioGenex.